Department of Oncology, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.
Clin Oncol (R Coll Radiol). 2013 Mar;25(3):162-70. doi: 10.1016/j.clon.2012.07.015. Epub 2012 Aug 18.
To validate our approach to target volume definition for intensity-modulated radiotherapy (IMRT) after induction chemotherapy and to analyse the pattern of treatment failure in patients with locoregionally advanced oropharyngeal squamous cell carcinoma (SCC) after sequential chemoradiotherapy (SCRT).
We studied all patients with locoregionally advanced oropharyngeal SCC treated with SCRT, definitive IMRT and no prior surgery between December 2004 and February 2010. SCRT consisted of three cycles of induction chemotherapy followed by IMRT with concurrent weekly chemotherapy. Our approach to IMRT tumour volume definition after induction chemotherapy was similar to recommendations from published clinical practice guidelines. Volumetric expansion was used to create the high-dose clinical target volume with a margin of 10 mm. The high-dose planning target volume (PTV) was treated to 65 Gy, whereas the prophylactic-dose PTV received 54 Gy over 30 fractions using the simultaneous integrated boost technique. The location and extent of each treatment failure was recorded, reconstructed on the planning computed tomography images and analysed using the dose distribution of the IMRT plan.
Fifty-two patients were included. The median follow-up was 32.2 months (range 5.0-67.1 months). There were seven local failures, no regional recurrences and one with distant disease. None of the patients required post-treatment neck dissection. All local failures were in-field and occurred within the high-dose PTV. There were no marginal recurrences. Actuarial recurrence-free, disease-specific and overall survival rates at 3 years were 83.9, 85.9 and 79.7%, respectively.
The absence of marginal recurrences validated the approach to IMRT target volume definition after induction chemotherapy proposed by clinical practice guidelines and practised at our institution. It suggested a lack of benefit with the use of larger geometric margins and additional anatomical expansion for the high-dose clinical target volume. SCRT resulted in excellent regional and distant disease control in patients with locoregionally advanced oropharyngeal SCC.
验证我们在诱导化疗后对强度调制放疗(IMRT)靶区定义的方法,并分析序贯放化疗(SCRT)后局部晚期或口咽鳞状细胞癌(SCC)患者的治疗失败模式。
我们研究了 2004 年 12 月至 2010 年 2 月期间所有接受 SCRT、确定性 IMRT 和无先前手术的局部晚期口咽 SCC 患者。SCRT 包括三个周期的诱导化疗,随后是 IMRT 联合每周化疗。我们在诱导化疗后进行 IMRT 肿瘤体积定义的方法与已发表的临床实践指南中的建议相似。使用容积扩张技术为高剂量临床靶区创建 10mm 的边缘。高剂量计划靶区(PTV)接受 65Gy 治疗,而预防性剂量 PTV 采用同时整合升压技术,30 次分割,每次 54Gy。记录每个治疗失败的位置和范围,在计划 CT 图像上重建,并使用 IMRT 计划的剂量分布进行分析。
共纳入 52 例患者。中位随访时间为 32.2 个月(范围 5.0-67.1 个月)。有 7 例局部失败,无区域复发,1 例远处转移。无患者需要治疗后颈部清扫术。所有局部失败均为场内,发生在高剂量 PTV 内。无边缘复发。3 年时的无复发生存率、疾病特异性生存率和总生存率分别为 83.9%、85.9%和 79.7%。
诱导化疗后 IMRT 靶区定义方法的无边缘复发验证了临床实践指南提出并在我们机构实践的方法。这表明对于高剂量临床靶区,使用更大的几何边缘和额外的解剖扩张并没有带来益处。SCRT 为局部晚期口咽 SCC 患者提供了极好的区域和远处疾病控制。